摘要
近年来,免疫治疗的兴起改变了非小细胞肺癌(non-small cell lung cancer,NSCLC)的治疗格局。抗血管生成药物使肿瘤局部血管正常化,有助于免疫效应细胞浸润,这一机制与免疫检查点抑制剂(immune checkpoint inhibitor,ICI)存在协同增效作用。本文将对抗血管生成药物与ICI联合治疗NSCLC的作用机制进行阐述,并对相关临床研究进行汇总分析,旨在为NSCLC患者提供更多的治疗选择。
The use of immunotherapy has revolutionized the treatment of patients with non-small cell lung cancer(NSCLC)in recent years.Anti-angiogenic agents can induce tumor vessel normalization and promote the infiltration of immune effector cells,which may synergize with immune checkpoint inhibitors(ICIs).In this paper,the mechanisms of anti-angiogenic agents combined with ICIs are illustrated,and relevant clinical studies are summarized and analyzed,in order to provide more treatment options for NSCLC patients.
作者
邱鲁鹏
孙卓雅
赵晓
焦顺昌
QIU Lupeng;SUN Zhuoya;ZHAO Xiao;JIAO Shunchang(Chinese PLA Medical School,Beijing 100853,China;Department of Oncology,the First Medical Center,Chinese PLA General Hospital,Beijing 100853,China)
出处
《解放军医学院学报》
CAS
北大核心
2022年第12期1288-1292,1297,共6页
Academic Journal of Chinese PLA Medical School
基金
国家自然科学基金项目(81972681)。
关键词
非小细胞肺癌
抗血管生成治疗
免疫检查点抑制剂
总生存期
安全性
non-small cell lung cancer
anti-angiogenic therapy
immune checkpoint inhibitors
overall survival
safety